Overview

This phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin

Eligibility

Inclusion Criteria:

• Written informed consent according to International Conference on Harmonisation (ICH)/ Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures.
• Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy, for prostatic adenocarcinoma previously treated by radical prostatectomy.
• Local recurrence in irradiated areas proven by biological (PSA > 0.2 ng/ml and ascending confirmed by at least 2 successive assays) and radiological (lesion visible on MRI and/or Choline PET and/or Prostate-Specific Membrane Antigen (PSMA) PET).
• Recurrence without rectal invasion
• Pelvic and prostate MRI evaluation
• Absence of pelvic lymph node or metastatic recurrence proven by choline PET or PSMA PET scan
• World Health Organisation (WHO) performance status 0-1
• Low risk, intermediate risk and high risk with a single risk factor
• PSA doubling time > 6 months
• No anti-cancer treatments planned for the current relapse, including hormone therapy.
• Age > 18 years old.
• Life expectancy greater than or equal to 5 years.
• Patient registered with a health insurance system.
• Patients willing and able to comply with the planned visits, treatment plan, laboratory tests and other study procedures indicated in the protocol.

Exclusion Criteria:

• Metastatic disease (bone, lymph node or other)
• Late radiotherapy urinary or gastrointestinal toxicity (grade ≥ 2) (after radiotherapy of prostate lodge)
• History of cancer in the 5 years prior to trial entry other than cutaneous basal cell carcinoma
• Inflammatory bowel disease
• Contraindications for performing MRI
• Rectal surgery history
• Patient treated for Diabetes
• Creatinine clearance < 45 mL/min
• Treatment with metformin in the last 3 months prior to inclusion
• Severe comorbidity that may affect treatment, for example :
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of inclusion.
  • Unstable angina, myocardial infarction and/or congestive heart failure requiring hospitalization within the last 6 months
  • Myocardial infarction in the last 6 months.
  • Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) or other respiratory conditions requiring hospitalization or preventing metformin therapy at the time of inclusion.
• Any condition associated with an increased risk of lactic acidosis (e.g., alcohol

  abuse, New York Heart Association (NYHA) III or IV congestive heart failure).

• Clinically significant history of hepatopathy with Child-Pugh B or C score, including viral infection or hepatitis, alcohol abuse or cirrhosis.
• Any acute or chronic condition that may result in tissue hypoxia (e.g. heart or respiratory failure, shock).
• Bilateral hip prosthesis
• Treatment with any investigational drug or participation in a clinical trial within 30 days prior to inclusion.
• Known hypersensitivity to metformin or any of its components
• Inability or reluctance to swallow oral medications
• Persons deprived of liberty, under a measure of safeguard of justice, under guardianship or under the tutor authority
• Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.